SynX

SynX Pharma was a specialized biotechnology company focused on the development and commercialization of rapid point-of-care diagnostic tests for cardiovascular and neurological conditions. The company's primary focus was its Nexus platform, which enabled the simultaneous detection of multiple biomarkers from a single blood sample to assist in the emergency diagnosis of congestive heart failure and myocardial infarction. Beyond cardiology, SynX expanded its research into proteomics-based diagnostics for traumatic brain injury and Alzheimer's disease. The company was acquired by Nanogen in 2004 to integrate its cardiac marker portfolio into Nanogen's molecular diagnostic offerings.